作者
Joost Smolders, Raymond Hupperts, Frederik Barkhof, Luigi ME Grimaldi, Trygve Holmoy, Joep Killestein, Peter Rieckmann, Myriam Schluep, Reinhold Vieth, Ulrike Hostalek, Lizette Ghazi-Visser, Manolo Beelke, SOLAR Study Group
发表日期
2011/12/15
期刊
Journal of the neurological sciences
卷号
311
期号
1-2
页码范围
44-49
出版商
Elsevier
简介
Recent studies have demonstrated the immunomodulatory properties of vitamin D, and vitamin D deficiency may be a risk factor for the development of MS. The risk of developing MS has, in fact, been associated with rising latitudes, past exposure to sun and serum vitamin D status. Serum 25-hydroxyvitamin D [25(OH)D] levels have also been associated with relapses and disability progression. The identification of risk factors, such as vitamin D deficiency, in MS may provide an opportunity to improve current treatment strategies, through combination therapy with established MS treatments. Accordingly, vitamin D may play a role in MS therapy. Small clinical studies of vitamin D supplementation in patients with MS have reported positive immunomodulatory effects, reduced relapse rates and a reduction in the number of gadolinium-enhancing lesions. However, large randomized clinical trials of vitamin D …
引用总数
201120122013201420152016201720182019202020212022202320245223014121799841241